All In Biotech

Investigational drug · Phase 2

Tacrolimus prolonged release

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Intestine Transplantation, Kidney Transplantation, Lung Transplantation.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

26

Any phase or sponsor naming "Tacrolimus prolonged release"

First trial start

2011

May 25, 2011

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Tacrolimus prolonged release", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Intestine Transplantation
  • Kidney Transplantation
  • Lung Transplantation
  • Liver Transplantation
  • Heart Transplantation

Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Tacrolimus prolonged release" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 11 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.